L
Lipella Pharmaceuticals Inc
NASDAQ:LIPO
Lipella Pharmaceuticals Inc
NASDAQ:LIPO
Price:
0.035
USD
Market Closed
Market Cap:
$161.7k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
L
|
Lipella Pharmaceuticals Inc
NASDAQ:LIPO
|
US |
|
G
|
GTN Textiles Ltd
BSE:532744
|
IN |
|
Lotus Resources Ltd
ASX:LOT
|
AU |
|
Micro Focus International PLC
LSE:MCRO
|
UK |
|
I
|
Imugene Ltd
OTC:IUGNF
|
AU |
|
U
|
UBS Group AG
SWB:0UB
|
CH |
|
Portmeirion Group PLC
LSE:PMP
|
UK |
|
I
|
Intellivate Capital Ventures Ltd
BSE:506134
|
IN |
|
Euro Ressources SA
PAR:EUR
|
FR |
|
Mizuno Corp
TSE:8022
|
JP |
|
S
|
Sanok Rubber Company SA
WSE:SNK
|
PL |
|
G
|
GS P&L Co Ltd
KRX:499790
|
KR |
|
Z
|
Zhejiang Biyi Electric Appliance Co Ltd
SSE:603215
|
CN |
|
S
|
Super Hi International Holding Ltd
HKEX:9658
|
SG |
|
C
|
CASI Pharmaceuticals Inc
NASDAQ:CASI
|
US |
|
Fujian Funeng Co Ltd
SSE:600483
|
CN |
|
H2APEX Group SCA
XETRA:H2A
|
LU |
|
K
|
KPM Holding Ltd
HKEX:8027
|
SG |
|
R
|
Ryvu Therapeutics SA
WSE:RVU
|
PL |
|
S
|
Summa Linguae Technologies SA
WSE:SUL
|
PL |
|
Vakrangee Limited
NSE:VAKRANGEE
|
IN |
|
Ora Gold Ltd
ASX:OAU
|
AU |
|
P
|
PVI Holdings
VN:PVI
|
VN |
|
Toho Gas Co Ltd
TSE:9533
|
JP |
Income Statement
Earnings Waterfall
Lipella Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
Income Statement
Lipella Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
Currency: USD
| Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
+64%
|
0
+35%
|
0
+17%
|
0
-6%
|
0
+6%
|
1
+6%
|
0
-5%
|
1
+11%
|
1
-3%
|
|
| Operating Income | |||||||||||
| Operating Expenses |
(3)
|
(4)
|
(6)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(6)
|
(6)
|
|
| Selling, General & Administrative |
(0)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
(2)
|
|
| Research & Development |
(3)
|
(3)
|
(4)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
|
| Operating Income |
(3)
N/A
|
(4)
-42%
|
(5)
-43%
|
(4)
+17%
|
(5)
-8%
|
(5)
-3%
|
(4)
+13%
|
(4)
-2%
|
(5)
-17%
|
(5)
-2%
|
|
| Pre-Tax Income | |||||||||||
| Interest Income Expense |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(0)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Pre-Tax Income |
(3)
N/A
|
(4)
-41%
|
(5)
-42%
|
(4)
+17%
|
(5)
-8%
|
(5)
-3%
|
(4)
+13%
|
(4)
-3%
|
(5)
-18%
|
(5)
-2%
|
|
| Net Income | |||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(3)
|
(4)
|
(5)
|
(4)
|
(5)
|
(5)
|
(4)
|
(4)
|
(5)
|
(5)
|
|
| Net Income (Common) |
(3)
N/A
|
(4)
-41%
|
(5)
-42%
|
(4)
+17%
|
(5)
-8%
|
(5)
-3%
|
(4)
+13%
|
(4)
-3%
|
(5)
-18%
|
(5)
-2%
|
|
| EPS (Diluted) |
-5.12
N/A
|
-0.63
+88%
|
-0.9
-43%
|
-0.74
+18%
|
-6.16
-732%
|
-5.2
+16%
|
-4.35
+16%
|
-3.8
+13%
|
-4.79
-26%
|
-2.49
+48%
|
|
Switch to:
Switch to:
See Also
Discover More
